Chiara Russo

How Endo's FDA Decision Affects Egalet

For Egalet, Clinical Delays Outweigh Solid Q4 And Arymo Launch

Egalet's Best-In-Class Opioid Abuse Deterrent Continues To Impress

For Egalet, Clinical Delays Outweigh Solid Q4 And Arymo Launch

Egalet's Best-In-Class Opioid Abuse Deterrent Continues To Impress

The FDA's Historic Caution On Abuse Deterrent Labeling

Why Egalet Investors Should Expect FDA Approval On Arymo By Year-End

The FDA's Historic Caution On Abuse Deterrent Labeling

Why Egalet Investors Should Expect FDA Approval On Arymo By Year-End

Why Egalet's FDA PDUFA Delay Is No Cause For Panic

Importance Of Phase 2 Trials

Chiara Russo Recent News

Importance Of Phase 1 Trials

Cantor Raises Price Target For Paratek Pharma, Sees 82% Upside

Cantor Doesn't Think BioDelivery Sciences Should Be Cutting To Grow, Downgrades Stock To Hold

Cantor Initiates Heron Therapeutics With Buy Rating, $41 Price Target

Proxy Battle: What's Happening Between Starboard And DepoMed?

DepoMed's Latest Acquisition: Too Good To Be True?

Analyst Sees Success For Tonix Pharmaceuticals Holdings Corp.